Novel Pseudonocardia sp. RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 14, 2005
app pub date -
Dec 2, 2004
filing date -
Jan 9, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention provides a novel microorganism Pseudonocardia sp. RMRC PAH4 characterized in that it is able to degrade high concentration of quinoline by enrichment culture, shows a high tolerance to compactin-sodium and possesses a high hydroxylation activity of converting compactin-sodium to pravastatin-sodium. The invention relates also a process for converting compactin-sodium into pravastatin-sodium by fermenting said novel microorganism Pseudonocardia sp. RMRC PAH4. Pravastain-sodium is a potent cholesterol-lowering agent used in treatment for hypercholesterolemia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully